Lymphedema - Pipeline Insight, 2025

DelveInsight’s, “Lymphedema – Pipeline Insight, 2025,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Lymphedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lymphedema Understanding

Lymphedema: Overview

Lymphedema is the condition that may be caused in the body due to cancer and as a side effect of the cancer treatment. It occurs due to the buildup fluids in soft body tissues which lead to swelling in the organs, particularly limbs. Lymphedema can lead to psychological, physical, and social problems in patients. Symptoms

Symptoms of lymphedema include loss of hair, troubled sleep, a burning sensation in legs, itching in toes and legs, a feeling of tightness when clothes, bracelets, shoes, etc. are worn, skin thickening without any changes in the skin, trouble moving arms or legs, heaviness in arms or legs, and swelling in arms or legs, which may include toes and fingers.

Diagnosis

Diagnosis may be based on past cancer history of the patient. Test such as Doppler ultrasound, CT scan, MRI scan, and radionuclide imaging of lymphatic system (lymphoscintigraphy) may be carried out.

Treatment

At present, there is no cure for lymphedema. The treatment is symptomatic and major focus is on controlling the pain and swelling. The treatment regimen may include massages, exercises, pneumatic compression, compression garments, and bandaging of the affected area.

Lymphedema Emerging Drugs Chapters

This segment of the Lymphedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, and phase I/II. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lymphedema Emerging Drugs

Lymfactin: Herantis Pharma

Lymfactin is a product which is being developed by Herantis Pharma. It is derived from the Vascular Endothelial Growth Factor C (VEGF-C), a natural human protein, which is crucial for the growth of new lymphatic vessels. Lymphfactin is a gene therapy product which works by the delivery of the human gene coding for VEGF-C, which in turn initiates the new lymphatic vessel formation. It is administered locally at the required site. It is currently available for licensing.

LYT-100:PureTechHealth

PureTech Health acquired LYT-100 in July 2019 from Auspex Pharmaceuticals. The drug candidate is in the phase I/II of drug development. The company believes that LYT-100 holds the potential to be evaluated for various inflammatory and fibrotic conditions besides being developed for lymphedema.

Further product details are provided in the report……..

Lymphedema: Therapeutic Assessment

This segment of the report provides insights about the different Lymphedema drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Lymphedema

There are approx. 10+ key companies which are developing the therapies for Lymphedema. The companies which have their Lymphedema drug candidates in the mid to advanced stage, i.e. phase III and Phase II include PureTech Health and others.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Lymphedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lymphedema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lymphedema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphedema drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Lymphedema R&D. The therapies under development are focused on novel approaches to treat/improve Lymphedema.

Lymphedema Report Insights

• Lymphedema Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lymphedema Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lymphedema drugs?
• How many Lymphedema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lymphedema?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lymphedema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lymphedema and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• PureTech Health
• Herantis Pharma

Key Products

• LYT-100
• Lymfactin